These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27773835)

  • 1. Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease.
    Nishijima H; Ueno T; Ueno S; Mori F; Miki Y; Tomiyama M
    Neurosci Res; 2017 Feb; 115():54-58. PubMed ID: 27773835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa treatment and dendritic spine pathology.
    Nishijima H; Ueno T; Funamizu Y; Ueno S; Tomiyama M
    Mov Disord; 2018 Jul; 33(6):877-888. PubMed ID: 28880414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Nishijima H; Arai A; Kimura T; Mori F; Yamada J; Migita K; Wakabayashi K; Baba M; Ueno S; Tomiyama M
    Neuropathology; 2013 Aug; 33(4):391-6. PubMed ID: 23241013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
    Nishijima H; Suzuki S; Kon T; Funamizu Y; Ueno T; Haga R; Suzuki C; Arai A; Kimura T; Suzuki C; Meguro R; Miki Y; Yamada J; Migita K; Ichinohe N; Ueno S; Baba M; Tomiyama M
    Mov Disord; 2014 Mar; 29(3):336-43. PubMed ID: 24573720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Cerasa A; Pugliese P; Messina D; Morelli M; Gioia MC; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A
    Mov Disord; 2012 Mar; 27(3):364-71. PubMed ID: 22076870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
    Funamizu Y; Nishijima H; Ueno T; Ueno S; Mizukami H; Yagihashi S; Tomiyama M
    Neurosci Res; 2017 Aug; 121():49-53. PubMed ID: 28392304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spine Enlargement of Pyramidal Tract-Type Neurons in the Motor Cortex of a Rat Model of Levodopa-Induced Dyskinesia.
    Ueno T; Nishijima H; Ueno S; Tomiyama M
    Front Neurosci; 2017; 11():206. PubMed ID: 28450828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease.
    Solis O; Limón DI; Flores-Hernández J; Flores G
    Synapse; 2007 Jun; 61(6):450-8. PubMed ID: 17372982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection for Parkinson's disease.
    Koller WC
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S155-9. PubMed ID: 9749588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.